Rankiteo Logo
Rankiteo
Leader in Cyber Underwriting
Loading...
NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop
WindowsmacOSLinux
Download

Comparison Overview

GenRx PharmacyGenRx Pharmacy
VS
Alkem Laboratories Ltd.Alkem Laboratories Ltd.
GenRx Pharmacy

GenRx Pharmacy

17250 North Hartford Drive, Scottsdale, 85255, US

Last Update: 28/03/2026

View Profile
Between 650 and 699
https://genrx2u.com
685/1000Weak

GenRx is a family owned pharmacy with two locations in Scottsdale, AZ. Opening in 2014 with a focus on dermatology. GenRx is a proven leader in the industry whose mission is to provide safe, high quality pharmacy services; excellent customer service; and clinical educat...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:34
Subsidiaries:0
12-month incidents
0
Known data breaches
0
Attack type number
1
Alkem Laboratories Ltd.

Alkem Laboratories Ltd.

Lower Parel, Alkem House , Mumbai, IN, 400013

Last Update: 01/04/2026

View Profile
Between 750 and 799
http://www.alkemlabs.com
775/1000Fair

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It wa...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:15,609
Subsidiaries:0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Ranges Comparison

Based On Specific Ai Models Category
GenRx Pharmacy

GenRx Pharmacy

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA
Alkem Laboratories Ltd.

Alkem Laboratories Ltd.

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for GenRx Pharmacy in 2026.

Incidents

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Alkem Laboratories Ltd. in 2026.

Incidents

Incident History - GenRx Pharmacy (X = Date, Y = Severity)

GenRx Pharmacy cyber incidents detection timeline including parent company and subsidiaries.

R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Incident History - Alkem Laboratories Ltd. (X = Date, Y = Severity)

Alkem Laboratories Ltd. cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Notable Incidents

Last Cyber / HR Incidents / Global...
GenRx Pharmacy

GenRx Pharmacy

Incidents
🔒 Incident : Ransomware
GEN202117222
🔒 Incident : Ransomware
GEN406072825
Alkem Laboratories Ltd.

Alkem Laboratories Ltd.

Incidents
No explicit notable incidents reported.

FAQ

Between GenRx Pharmacy company and Alkem Laboratories Ltd. company, which one has the best AI Cybersecurity Score ?
Between GenRx Pharmacy company and Alkem Laboratories Ltd. company, which one has experienced more cyber incidents in the past ?
Between GenRx Pharmacy company and Alkem Laboratories Ltd. company, which one has experienced more cyber incidents this year ?
Between GenRx Pharmacy company and Alkem Laboratories Ltd. company, which one has experienced at least one ransomware attack ?
Between GenRx Pharmacy company and Alkem Laboratories Ltd. company, which one has experienced at least one data breach ?
Between GenRx Pharmacy company and Alkem Laboratories Ltd. company, which one has experienced at least one targeted cyberattack ?
Between GenRx Pharmacy company and Alkem Laboratories Ltd. company, which one has experienced at least one vulnerability ?
Between GenRx Pharmacy company and Alkem Laboratories Ltd. company, which one holds the most compliance certifications ?
Between GenRx Pharmacy company and Alkem Laboratories Ltd. company, which one holds the fewest compliance certifications ?
Between GenRx Pharmacy company and Alkem Laboratories Ltd. company, which one has the most subsidiaries ?
Between GenRx Pharmacy company and Alkem Laboratories Ltd. company, which one has the largest number of employees ?
Between GenRx Pharmacy and Alkem Laboratories Ltd., which company holds both SOC 2 Type 1 certifications ?
Between GenRx Pharmacy and Alkem Laboratories Ltd., which company holds both SOC 2 Type 2 certifications ?
Which company is ISO 27001 certified - GenRx Pharmacy or Alkem Laboratories Ltd. ?
Which company is PCI DSS compliant - GenRx Pharmacy or Alkem Laboratories Ltd. ?
Between GenRx Pharmacy and Alkem Laboratories Ltd., which company complies with HIPAA regulations for healthcare data ?
Between GenRx Pharmacy and Alkem Laboratories Ltd., which company complies with GDPR requirements ?

Latest Global CVEs

CVE-2026-16174
SUMMARY

Netskope was notified about a potential gap in Netskope Endpoint DLP (EPDLP) running on Windows systems. Successful exploitation of the gap could potentially allow a privileged user to send a crafted message to the EPDLP process port to trigger an integer overflow, leading to memory corruption. Successful exploitation would require the EPDLP module to be enabled in the client configuration, and that Memory Integrity is disabled. A successful exploit could potentially result in a denial-of-service, arbitrary code execution, or privilege escalation on the local machine.

PUBLISHED
Date2026-09-10
UPDATED
Date2026-09-10
RISK INFORMATION (Score: )
CVSS4
Base Score: 8.7
Complexity: LOW
CVSS:4.0/AV:L/AC:L/AT:P/PR:H/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
NA
EXPLOITABILITY
NA
CVE-2026-16172
SUMMARY

Netskope was notified of an out-of-bounds heap read affecting the Endpoint DLP (EPDLP) service of the Netskope Client. A local standard user could potentially send a specially crafted message that is not properly validated with a bounds check, likely crashing the kernel driver handler. Successful exploitation could potentially crash the EPDLP service, temporarily interrupting DLP enforcement. A successful exploit could potentially also reveal per-boot memory layout information to unauthorized users.

PUBLISHED
Date2026-09-10
UPDATED
Date2026-09-10
RISK INFORMATION (Score: )
CVSS4
Base Score: 6.0
Complexity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:L/SC:N/SI:N/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
NA
EXPLOITABILITY
NA
CVE-2026-87958
SUMMARY

IBM Db2 11.5.0 through 11.5.9, and 12.1.0 through 12.1.5 is vulnerable to a denial of service where a specific functionality on a Db2 server can be disabled by a privileged user under certain conditions.

PUBLISHED
Date2026-09-10
UPDATED
Date2026-09-10
RISK INFORMATION (Score: 8.1)
CVSS3
Base Score: 8.1
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:H
IMPACT SCORE
5.2
EXPLOITABILITY
2.8
CVE-2026-86093
SUMMARY

IBM Db2 11.5.0 through 11.5.9, and 12.1.0 through 12.1.5 could allow an attacker with the ability to control or impersonate a DRDA server endpoint to execute arbitrary commands on Db2 clients due to a stack-based buffer overflow that improperly copies user-controlled data into a fixed-size stack buffer without bounds checking.

PUBLISHED
Date2026-09-10
UPDATED
Date2026-09-10
RISK INFORMATION (Score: 7.5)
CVSS3
Base Score: 7.5
Complexity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:H/I:H/A:H
IMPACT SCORE
5.9
EXPLOITABILITY
1.6
CVE-2026-86087
SUMMARY

IBM Db2 11.5.0 through 11.5.9, and 12.1.0 through 12.1.5 could allow an authenticated user to send a specially crafted request to write arbitrary files on the system.

PUBLISHED
Date2026-09-10
UPDATED
Date2026-09-10
RISK INFORMATION (Score: 4.3)
CVSS3
Base Score: 4.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N
IMPACT SCORE
1.4
EXPLOITABILITY
2.8